Impact ledger

SK Biopharmaceuticals Co., Ltd. (SKBPF): the developments shaping its investment case

Follow the evidence affecting SK Biopharmaceuticals Co., Ltd.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

Research SK Biopharmaceuticals Co., Ltd. · $399/mo

Test assumptions, examine opportunities, and save your research.

Material developments

2026-08-26

SK Biopharmaceuticals Co., Ltd. to Acquire Biohaven Ltd. ($795M)

Channel: Strategic expansion into new therapeutic areas and pipeline diversification, balanced by upfront and potential milestone payments.

mixed· 3-12m

2026-08-28 · 2 reports

Biohaven partners with SK Biopharmaceuticals in $795M licensing deal

Channel: Expansion of pipeline and potential for future revenue streams.

Bullish· 3-12m

Event impact log

3 events mapped to SKBPF since 2026-08-26. Evidence through 2026-08-28.

Date	Event	Channel	Direction	Horizon	Impact
2026-08-28	Biohaven partners with SK Biopharmaceuticals in $795M licensing deal	Expansion of pipeline and potential for future revenue streams.	Bullish	3-12m	0.60
2026-08-28	Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim	Strategic pipeline expansion and potential future revenue streams, balanced by upfront investment.	mixed	3-12m	0.60
2026-08-26	SK Biopharmaceuticals Co., Ltd. to Acquire Biohaven Ltd. ($795M)	Strategic expansion into new therapeutic areas and pipeline diversification, balanced by upfront and potential milestone payments.	mixed	3-12m	0.60

Continue this research

Build your SK Biopharmaceuticals Co., Ltd. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.